As it advances with a purchase of Intra-Cellular Therapies (NASDAQ:ITCI), Johnson & Johnson (NYSE:JNJ) runs the danger of losing its AAA credit rating. Concerned about the possible increase in debt connected to the acquisition, S&P Global Ratings intends to review J&J's rating.
S&P also highlights the possibility of future acquisitions supported by borrowing, which begs concerns over J&J's capacity to keep its top-tier reputation. Should downgrading, Microsoft (NASDAQ:MSFT) would be the only US corporation with a AAA rating. Just seven companies worldwide still maintain this distinction: Temasek Holdings and Public Sector Pension Investment Board.
Moody's, meantime, backs J&J's AAA rating by stressing its $20 billion cash reserve and robust cash flow. Targeting to close the sale within the year, the company intends to pay the acquisition cost using a mix of cash and borrowing
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.